Giulio Cerea

Giulio Cerea

Ospedale Niguarda Ca' Granda, Milan - Milano / Italy
Natural Sciences / Molecular Biology & Genetics
AD Scientific Index ID: 4984882
person_outline Giulio Cerea's MOST POPULAR ARTICLES
1-) Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)A Drilon, S Siena, SHI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ...Cancer discovery 7 (4), 400-409, 20177032017
2-) Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal … G Cerea, M Vaghi, A Ardizzoia, S Villa, R Bucovec, S Mengo, G Gardani, ... Anticancer research 23 (2C), 1951-1954, 2003 1352003
3-) Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: Combined results from two phase I trials (ALKA-372-001 and STARTRK-1) Cancer … A Drilon, S Siena, SI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ... Published by S. Karger AG, Basel www. karger. com/cro Gupta et al.: A …, 2019 1252019
4-) First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance statusF Facchinetti, G Mazzaschi, F Barbieri, F Passiglia, F Mazzoni, R Berardi, ...European Journal of Cancer 130, 155-167, 20201252020
5-) Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancerA Amatu, A Somaschini, G Cerea, R Bosotti, E Valtorta, P Buonandi, ...British journal of cancer 113 (12), 1730-1734, 2015832015